EANS-Adhoc: Epigenomics AG: General Assembly Approves all Proposals including Reduction of Share Capital with vast majority

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/molecular diagnostic

28.06.2011

Berlin, Germany, June 28, 2011 - Epigenomics AG`s (ISIN:
DE000A0BVT96) General Assembly today approved all decision proposals
by the management with vast majority.

The proposal to reduce the share capital and to consolidate of the
shares at a ratio of 5:1 was approved with more than 99.8 % of the
present and represented voting rights. Following this approval, the
capital shall be reduced from now EUR 44,092,085.00 to EUR
8,818,417.00. After the consolidation of the shares, the share
capital shall be distributed into 8,818,417 shares. The reduction of
share capital becomes effective only after its registration in the
commercial register. The consolidation of the shares shall follow
thereafter in the subsequent trading days.

An overview of all voting results of the General Assembly is
available at Epigenomics AG´s internet page.

-End of Ad hoc -

Further Information

For the voting results and further information on Epigenomics AG´s
Annual General Shareholder´s Meeting please visit http://www.epigenom
ics.com/news-investors/investor-relations/hauptversammlung.html

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Phone: +49 (0) 30 24345 0
ir@epigenomics.com
www.epigenomics.com

Epigenomics´ legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

Further inquiry note:
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: www.epigenomics.com
sector: Biotechnology
ISIN: DE000A0BVT96, DE000A0XFWF2
indexes: Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, München
language: English